HC Wainwright Issues Positive Forecast for Harrow (NASDAQ:HROW) Stock Price

Harrow (NASDAQ:HROW) had its price objective hoisted by analysts at HC Wainwright from $64.00 to $69.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 78.11% from the stock’s previous close.

Several other research firms have also issued reports on HROW. B. Riley reiterated a “buy” rating and set a $74.00 target price (up from $70.00) on shares of Harrow in a report on Wednesday, October 1st. Zacks Research lowered Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. Craig Hallum lifted their price objective on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $94.00 target price on shares of Harrow in a report on Tuesday. Finally, Lake Street Capital increased their target price on Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $72.33.

Harrow Stock Performance

Shares of HROW stock opened at $38.74 on Wednesday. The company’s fifty day moving average price is $40.67 and its 200-day moving average price is $34.84. The stock has a market cap of $1.43 billion, a PE ratio of -154.96 and a beta of 0.19. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. Harrow has a 12 month low of $20.85 and a 12 month high of $54.19.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.11. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The company had revenue of $71.64 million during the quarter, compared to analyst estimates of $73.70 million. On average, equities analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Trading of Harrow

Several institutional investors have recently added to or reduced their stakes in HROW. AXQ Capital LP bought a new stake in shares of Harrow in the 3rd quarter worth $323,000. Profund Advisors LLC bought a new position in shares of Harrow during the third quarter valued at $328,000. Oppenheimer & Co. Inc. boosted its position in shares of Harrow by 12.6% during the third quarter. Oppenheimer & Co. Inc. now owns 14,994 shares of the company’s stock valued at $722,000 after buying an additional 1,677 shares during the last quarter. Independent Advisor Alliance bought a new stake in Harrow in the 3rd quarter worth about $210,000. Finally, AlphaQuest LLC increased its holdings in Harrow by 743.0% in the 3rd quarter. AlphaQuest LLC now owns 3,819 shares of the company’s stock worth $184,000 after buying an additional 3,366 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.